Skip to content

The clinical efficacy of local anesthesia drugs in relieving allodynia in different ways

Study for the effect of cyclooxygenase-2 inhibitor on CCI model rats, and the mechanism of prevention of postherpetic neuralgia, and the clinical efficacy of local anesthesia drugs in relieving allodynia

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900020751
Enrollment
Unknown
Registered
2019-01-16
Start date
2019-01-15
Completion date
Unknown
Last updated
2019-01-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

herpes zoster neuralgia

Interventions

Group 1:Use external support to remove clothing friction
Group 2:Use external support to remove clothing friction
Group 3:Use external support to remove clothing friction

Sponsors

Sichuan Academy of Medical Sciences & Sichuan People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
55 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) meet HZ/PHN diagnostic criteria: in patients with hypersensitivity to pain sensation in the nerve distribution area of trunk cadre, all herpes scabs were formed; (2) visual analogue score (VAS) of local touch-induced pain is greater than or equal to 4 points; (3) duration of illness: 1-3 months; (4) middle-aged and elderly patients between 55 and 75 years old met the inclusion criteria; (5) herpetic neuralgia is mainly distributed in chest, back, waist, abdomen and other trunk cadres, with no local skin damage; (6) all patients received standardized oral medication: gabapentin 0.3-0.9g tid or lerikka 75-225mg bid; Cobalamin tablet 0.5mg tid; (7) Normal lung function, liver, kidney, electrolyte function, blood glucose and blood pressure control stable. (8) an informed consent was signed.

Exclusion criteria

Exclusion criteria: (1) those who do not meet the HZ/PHN diagnostic criteria; (2) patients without touch-induced pain (hypersensitivity to pain sensation); (3) patients with serious cardiovascular, cerebrovascular, liver, kidney, hematopoietic system and other primary diseases or systemic failure, malignant tumors, mental patients; (4) combined with other potential diseases causing neuralgia, it is not clear that pain is caused by herpes zoster alone; (5) critically ill patients who are difficult to make a correct evaluation of the effectiveness and safety of treatment; (6) With other neurological diseases and mental diseases, epileptic seizure, hemiplegia and aphasia, no history of other system tumors; with obvious abnormalities in heart.

Design outcomes

Primary

MeasureTime frame
pain score;

Countries

China

Contacts

Public ContactDai Yuee

Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospita

42811388@qq.com+86 17708130201

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026